Global ADC Linker & Conjugation Technologies Markets to 2030 - Featuring Executive Insights from Stakeholders in Miracogen, NBE Therapeutics, Synaffix and EUCODIS Bioscience

News provided by

Feb 18, 2020, 10:15 ET

DUBLIN, Feb. 18, 2020 /PRNewswire/ -- The "Antibody Drug Conjugates (ADCs) - Linker and Conjugation Technologies Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current landscape and the likely future opportunities within the ADC linker and conjugation technologies market, over the next 10-12 years.

One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for ADC linker and conjugation technologies. Based on likely licensing deal structures and agreements that are expected to be inked in the foreseen future, we have provided an informed estimate of the evolution of the market for the period 2019-2030.

The report also features the likely distribution of the current and forecasted opportunity across the:

[A] type of linker (cleavable, non-cleavable and both)
[B] type of conjugation (chemical, enzymatic and others)
[C] key technologies
[D] key geographical regions (North America, Europe and Asia Pacific/Rest of the World)

With six approved drugs, namely POLIVY (2019), LUMOXITI (2018), BESPONSA (2017), MYLOTARG (2017, reapproval), KADCYLA (2013) and ADCETRIS (2011), and more than 200 in the pipeline (clinical/preclinical stages), antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics.

The success of this relatively novel class of therapeutics is attributed to the ability of lead molecules to specifically identify and eliminate disease associated cells/pathogens, consequently, addressing most of the concerns related to off target toxicities. In this context, the role of the linker molecule and the conjugation technology used is pivotal. In fact, conjugation chemistry has been shown to be directly related to the drug to antibody ratio (DAR) achieved, and thereby, governs the pharmacokinetic and pharmacodynamic properties of an ADC. Over time, a variety of other conjugated therapeutics have also been developed and are under evaluation.

Conventional conjugation technologies used for the development of ADCs exploited the superficial lysine residues that were inherent to the native antibody structure, or the inter-chain cysteine residues, for drug-linker attachment. Over time, the evolution of recombinant DNA technology and advances in conjugation techniques, have enabled researchers to significantly improve the bioconjugation process. In fact, next-generation conjugation technologies use artificially integrated lysine/cysteine residues in order to improve the DAR of the resulting conjugate.

Additionally, there are multiple technologies that claim to offer site-specific conjugation. There are a number of other noteworthy developments in the conjugation technologies domain, which include a variety of competent platforms based on various ligation, disulfide rebridging and protein remodeling approaches. Further, linker technologies have also evolved substantially, and there is vast array of linkers, including cleavable and non-cleavable variants, which are designed to govern drug release mechanism of conjugated therapeutic molecules.

It is worth highlighting that multiple licensing agreements/collaborations have been inked between drug developers and technology providers to advance the development of pipeline ADC candidates. Over the years, a number of start-ups/small companies, offering novel conjugation technologies, more potent cytotoxins/warheads and advanced linker chemistries, have been established to facilitate development of ADCs and other conjugated pharmaceuticals. We anticipate this niche and upcoming market to witness substantial growth over the coming years.

In addition to other elements, the report includes:

An overview of the overall landscape of ADC linker and conjugation technologies, featuring an in-depth analysis of the technologies, based on a number of parameters, such as type of technology, generation of the technology (first, second and third), type of linker (cleavable, non-cleavable), type of conjugation (chemical, enzymatic and others), site specificity (specific and non-specific), DAR of the ADCs developed, patent availability, and licensing activity. In addition, the chapter highlights a detailed landscape of linker and conjugation technologies developers and analysis based on parameters, such as year of establishment, company size and geographical location.
Elaborate profiles of prominent technology developers engaged in this domain. Each profile features a brief overview of the company, its financial information (if available), information on its technology portfolio, recent developments and an informed future outlook.
An analysis of the partnerships that have been established in the recent past, covering licensing agreements, product development and commercialization agreements, research and development agreements, product integration agreements, combination therapy development agreements, platform utilization agreements, and other relevant agreements.
A list of ADC therapeutic developers that are anticipated to partner with technology providers in future based on a detailed analysis of relevant parameters, such as availability of existing partners, availability of inhouse technology, company size (employee count), company's ADC pipeline strength, likely partners and development status of the ADC molecules.
A detailed competitiveness analysis of ADC linker and conjugation technologies, taking into consideration the supplier power (based on the year of establishment of developer) and key technology specifications, such as ADC generation, type of linker, DAR of the ADCs developed using the technology, availability of patent protection, number of deals signed for a particular technology (2016-2019), and popularity of the technology (in terms of the number of ADCs developed using the technology).
An in-depth analysis of the various patents that have been filed/granted related to linker/conjugation technologies till August 2019, taking into consideration parameters, such as patent type, publication year, issuing authority/patent offices involved, CPC symbol, emerging focus areas and leading industry/academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.

In order to account for future uncertainties and add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Key Topics Covered

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Antibody-based Therapeutics
3.3 Antibody Drug Conjugates (ADCs)
3.3.1 Components of ADCs
3.3.1.1 Antibody
3.3.1.2 Cytotoxin
3.3.1.3 Linker
3.4. Advantages of ADCs over Traditional Pharmacological Interventions
3.5. ADC Linker Technologies
3.5.1. Non-cleavable Linkers
3.5.2. Cleavable Linkers
3.6. ADC Conjugation Technologies
3.6.1. Chemical Conjugation
3.6.2. Enzymatic Conjugation
3.7. Future Perspectives

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. ADC Linker and Conjugation Technologies: Overall Market Landscape
4.2.1. Analysis by Type of Technology
4.2.2. Analysis by ADC Generation
4.2.3. Analysis by Type of Linker
4.2.4. Analysis by Type of Conjugation
4.2.5. Analysis by Site Specificity
4.2.6. Analysis by Drug to Antibody Ratio
4.2.7. Analysis by Patent Availability
4.2.8. Analysis by Licensing Activity
4.3. ADC Linker and Conjugation Technologies: Developer Landscape
4.3.1 Analysis by Year of Establishment
4.3.2 Analysis by Company Size
4.3.3 Analysis by Geographical Location
4.3.4 Leading ADC Developers: Analysis by Number of Technologies
4.3.5 Grid Representation: Analysis by ADC Generation, Type of Linker, Company Size, and Geographical Location
4.3.6 World Map Representation: Analysis by Geography
4.4 ADC Linker and Conjugation Technologies: Service Providers

5. COMPANY PROFILES
5.1 Chapter Overview
5.2 Key Players in North America
5.2.1 Ambrx
5.2.1.1 Company Overview
5.2.1.2 Technology Overview
5.2.1.3 Recent Developments and Future Outlook
5.2.2 Catalent Biologics
5.2.3 Immunomedics
5.2.4 Mersana Therapeutics
5.2.5 Seattle Genetics
5.2.6 Sutro Biopharma
5.3 Key Players in Europe and Asia
5.3.1 Iksuda Therapeutics
5.3.2 LegoChem Biosciences
5.3.3 LinXis
5.3.4 NBE Therapeutics

6. PARTNERSHIPS AND COLLABORATIONS
6.1 Chapter Overview
6.2 Partnership Models
6.3 List of Partnerships and Collaborations
6.3.1 Analysis by Year of Partnership
6.3.2 Analysis by Type of Partnership
6.3.3 Analysis by Type of Linker
6.3.4 Analysis by Type of Conjugation
6.3.5 Analysis by Year of Partnership and Type of Partner
6.3.6 Analysis by Type of Partnership and Type of Partner
6.3.7 Most Active Players: Analysis by Number of Partnerships
6.3.8 Most Popular Technologies: Analysis by Number of Partnerships
6.3.9 Regional Analysis
6.3.10 Intercontinental and Intracontinental Agreements

7. LIKELY PARTNERS ANALYSIS
7.1 Chapter Overview
7.2 Scope and Methodology
7.3 ADC Linker and Conjugation Technologies: Potential Strategic Partners in North America
7.3.1 Most Likely Partners
7.3.2 Likely Partners
7.3.3 Less Likely Partners
7.4 ADC Linker and Conjugation Technologies: Potential Strategic Partners in Europe
7.5 ADC Linker and Conjugation Technologies: Potential Strategic Partners in Asia-Pacific

8. TECHNOLOGY COMPETITIVENESS ANALYSIS
8.1 Chapter Overview
8.2 Methodology
8.3 Assumptions and Key Parameters
8.4 Technology Competitiveness Analysis
8.4.1 Technologies Developed by Companies based in North America
8.4.2 Technologies Developed by Companies based in Europe
8.4.3 Technologies Developed by Companies based in Asia Pacific / RoW

9. PATENT ANALYSIS
9.1 Chapter Overview
9.2 Scope and Methodology
9.3 ADC Linker and Conjugation Technologies: Patent Portfolio
9.3.1 Analysis by Publication Year
9.3.2 Analysis by Issuing Authority / Patent Offices Involved
9.3.3 Analysis by CPC Symbols
9.3.4 Emerging Focus Areas
9.3.5 Analysis by Type of Company / Organization
9.3.6 Leading Assignees: Analysis by Number of Patents
9.4 ADC Linker and Conjugation Technologies: Patent Benchmarking Analysis
9.4.1 Analysis by Patent Characteristics
9.5 ADC Linker and Conjugation Technologies: Patent Valuation Analysis

10. NOVEL CONJUGATION TECHNOLOGY PLATFORMS
10.1 Chapter Overview
10.2 First Generation ADC Technologies
10.3 Second Generation ADC Technologies
10.3.1 Cysteine and Selenocysteine Engineering
10.3.2 Unnatural Amino Acid Engineering
10.3.3 Amino-Terminal Serine Engineering
10.4 Third Generation ADC Technologies
10.4.1 Enzyme-Assisted Ligation Approaches
10.4.2 Glycan Remodeling Approaches
10.4.3 Ligation at Fab Nucleotide-Binding Site
10.4.4 Cysteine Rebridging
10.4.5 Avoiding or Limiting Retro-Michael Drug Deconjugation
10.5 Evolutionary Analysis

11. MARKET SIZING AND FORECAST
11.1 Chapter Overview
11.2 Forecast Methodology and Key Assumptions
11.3 Global ADC Linker and Conjugation Technologies Market, 2019-2030
11.4 Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2019-2030
11.5 Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2019-2030
11.6 Global ADC Linker and Conjugation Technologies Market: Share of Key Technologies, 2019-2030
11.7 Global ADC Linker and Conjugation Technologies Market: Distribution by Region, 2019-2030
11.7.1 ADC Linker and Conjugation Technologies Market in North America, 2019-2030
11.7.2 ADC Linker and Conjugation Technologies Market in Europe, 2019-2030
11.7.3 ADC Linker and Conjugation Technologies Market in Asia Pacific, 2019-2030

12. EXECUTIVE INSIGHTS
12.1 Chapter Overview
12.2 Miracogen
12.2.1 Company Snapshot
12.2.2 Interview Transcript: Mary Hu, Chief Executive Officer
12.3 NBE Therapeutics
12.4 Synaffix
12.5 EUCODIS Bioscience

13. CONCLUDING REMARKS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

3P Biopharmaceuticals
3SBio
AbbVie
AbGenomics
ABL Bio
Abnova
Abzena
ACES Pharma
ADC Biotechnology
ADC Therapeutics
Advanced Proteome Therapeutics
Affinity Life Sciences
AGC Biologics
Agensys
Ajinomoto
Ajinomoto Bio-Pharma Services
Albumedix
Alexion Pharmaceuticals
Allergan
Alpha Cancer Technologies
Alta Partners
Alteogen
Ambrx
Amgen
Angiex
Antikor Biopharma
Araris Biotech
Asana BioSciences
Astellas Pharma
AstraZeneca
Avacta Life Sciences
Bayer
BeiGene
BioAtla
BioCapital
Biogen
BioLegend
BioMed Valley Discoveries
BioOutsource
Bio-Rad Laboratories
Bio-Synthesis
Biotechnique
Biotest
Bio-Thera Solutions
BlinkBio
Bliss Biopharmaceutical
BOC Sciences
Boehringer Ingelheim
Boster Biological Technology
Bristol-Myers Squibb
BSP Pharmaceuticals
Cancer Research UK
Capra Science Antibodies
CARBOGEN AMCIS
Cascadian Therapeutics
Catalent Biologics
Celgene
CellMosaic
Cell Signalling Technology
Cellerant Therapeutics
Celltrion
Centrose
Cerbios-Pharma
Chugai Pharmaceutical
Cisbio
Clovis Oncology
Concortis Biotherapeutics
Corixa
Creative Biolabs
Creative Diagonostics
Creative peptides
CSPC Pharmaceutical Group
CureMeta
Cytogen
CytomX Therapeutics
Daiichi Sankyo
Dalton Pharma Services
Debiopharm Group
Dyax
Eisai
Elan Pharmaceuticals
Eli Lilly
Elusys Therapeutics
EMD Serono
Envigo
Esperance Pharmaceuticals
EUCODIS Bioscience
Eventide Asset Management
Everest Biotech
Everest Medicines
Exelixis
Expedeon
Femtogenix
Fleet Bioprocessing
Formation Biologics
Formosa Laboratories
Fortis Therapeutics
Fosun Pharma
GamaMabs Pharma
Genentech
Genmab
Genovis
GenScript
Genzyme
GlaxoSmithKline
Glycotope
Glythera
Goodwin Biotechnology
GT Biopharma
Hangzhou DAC Biotech
Heidelberg Pharma
Hengrui Medicine
Human Genome Sciences
iBioSource
Iconic Therapeutics
Iksuda Therapeutics
ImClone Systems
ImmunoBiochem
ImmunoGen
Immunomedics
Innate Pharma
Innovate UK
IntoCell
IONTAS
iProgen Biotech
Iterum Therapeutics
Janssen Biotech
Johnson & Johnson
Johnson Matthey
Kairos Therapeutics
KLUS Pharma
Kyowa Hakko Kirin
LakePharma
LegoChem Bioscienses
Leinco Technologies
Leukemia & Lymphoma Society
Levena Biopharma
Life Technologies
Light Chain Bioscience
Lilly Ventures
LinXis
MabPlex
MabSpace Biosciences
MabVax Therapeutics
MacroGenics
Magenta Therapeutics
Maine Biotechnology
MediaPharma
MedImmune
Meditope Biosciences
MedKoo Biosciences
Memorial Sloan Kettering Cancer Center
Menarini Group
Merck
Mersana Therapeutics
Millennium Pharmaceuticals
Mitsubishi Tanabe Pharma
MorphoSys
Morphotek
MuseChem
NanoValent Pharmaceuticals
National Research Council of Canada
NBE-Therapeutics
NeoRx
Nexthera Capital
Nordic Nanovector
Noria Pharmaceuticals
Novartis
NovaTeinBio Novimmune
NovoCodex Biopharmaceuticals
Novozymes
OBI Pharma
OcellO
OGD2 Pharma
Oncolinx
Oncomatryx Biopharma
Oncotec Pharma Produktion
Organon Teknika
OriGene Technologies
Oxford BioTherapeutics
Palatin Technologies
Pfizer
Pharmaron
Philochem
Pierre Fabre
Piramal Pharma Solutions
ProBioGen
Progenics Pharmaceuticals
ProteoGenix
Puma Biotechnology
Rakuten Medical
Recepta Biopharma
Redwood Bioscience
Regeneron Pharmaceuticals
RemeGen
Roche
Rockland Immunochemicals
SafeBridge Consultants
Samsung Medical Center
Sanofi
Seattle Genetics
Seramun Diagnostica
Servier
Sesen Bio
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
Shanghai Jiaolian Medicine Research and Development
Shanghai Miracogen
Shenogen Pharma
Shire
Siamab Therapeutics
Skyline Ventures
Sorrento Therapeutics
SOTIO
SouthernBiotech
Sun Pharmaceutical Industries
Sunomix Biosciences
Surveyor Capital
Sutro Biopharma
SV Health Investors
Swedish Orphan Biovitrum (Sobi)
Synaffix
Syngene International
Synthon
TaiMed Biologics
Takeda Pharmaceutical
TBD-Biodiscovery
Teresi Pharmaceuticals
Teva Pharmaceutical
The Johns Hopkins University School of Medicine
The University of Texas MD Anderson Cancer Center
Theratechnologies
Thermo Fisher Scientific
ThioLogics
TOT BIOPHARM
Triphase Accelerator
Tsuchikama Laboratory
UCB
Ultragenyx Pharmaceutical
United Therapeutics
UW Carbone Cancer Center
Vaccinex
Valeant Pharmaceuticals
VelosBio
Vida Ventures
Visterra
WuXi Biologics
Wyeth
Xintela
Yale Cancer Center
Y-Biologics
Zhejiang Hisun Pharmaceutical
Zymeworks

For more information about this report visit https://www.researchandmarkets.com/r/l6ez8g

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets